Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Agbioscience

350. Elevate Ventures’ Matt Tyner on the cost of innovation + the role of the investor in this next era of venture capital

03 Mar 2025

Description

Pitchbook reports that of venture capital deals in 2024, roughly 30% of them were down rounds or flat, meaning their valuation of the companies either went backwards or were the same round to round. It’s a trend that will continue, so how can entrepreneurs break the cycle? Matt Tyner, managing partner of America’s most active venture capital firm – Elevate Ventures, joins today to make sense of what’s ahead and how innovators can succeed. He gets into:  The current state of venture capital – and the criticality of taking a step back to understand where things sit today Investors’ increased focus on profitability and not being able to cut your way to growth Artificial intelligence as an enabler – not a vertical  Does the future include a shift to debt versus venture The cost of innovation and the role of an investor in this era of venture capital What the current conversation with portfolio companies looks like for Elevate Ventures What Matt sees as emerging trends in agbioscience The most important jobs to be done in the industry 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.